Toggle menu

SABER

Start date:
May 2018
End date:
October 2020
Co-ordinated by:
University of Glasgow
Main trial site:
Queen Elizabeth University Hospital

Septic arthritis is difficult to diagnose because clinical presentations overlap with non infectious causes and laboratory, imaging, synovial and blood tests are insensitive. Although relatively uncommon, septic arthritis can be severely destructive to joints so the impetus is to give treatment without delay, often prior to a definitive diagnosis. This means patients can undergo invasive procedures, hospital admissions and antibiotics unnecessarily. This brings attendant risks in expanding antibiotic resistance and expense. This study aims to identify biomarkers in blood, urine and synovial fluid that are unique to patients with septic arthritis in order to aid in the rapid and accurate stratification of the acute joint presentation.

Primary objective: To identify blood, urine and synovial fluid biomarkers that are unique to patients with septic arthritis.

Secondary Objective: To determine, through whole genome sequencing of bacterial isolates, whether they are unique to septic arthritis and if there are any molecular signatures associated with a poor structural and systemic prognosis.

Sample: Adults presenting to the Emergency department with likely septic arthritis in one joint or more.

Target: 100

Trail design: Cross sectional proof of concept study

Chief Investigator

Local PI

Polly Black

Senior Research Nurse

More EMERGE Trials

Strokes caused by a clot are described as ischaemic. When patients experience ischaemic strokes they may be eligible for “clot busting” therapy (thrombolysis). Currently thrombolysis has been shown to improve patient outcome after a stroke if administered within the first 4.5 hours after stroke onset. Up to 25% of patients wake up with symptoms of a stroke. This means they have an unknown onset time for their stroke (so called ‘wake up strokes’). With no known onset time, they are ineligible for thrombolysis. This study will investigate how we might determine stroke onset time.

Read more

MRI in Acute Stroke

The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme

Read more

EMERGE Biobank

Developing a bioresource for all emergency presentations

Auditting, monitoring and optimising the transfusion support given to trauma patients in Scotland

Read more

Code Red

Transfusion and Laboratory support in Trauma Group Code Red Audit